Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director International S.C.A. Artal Acquires 16,173,800 Shares

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXGet Rating) Director International S.C.A. Artal purchased 16,173,800 shares of the business’s stock in a transaction on Monday, August 1st. The stock was bought at an average cost of $2.50 per share, with a total value of $40,434,500.00. Following the purchase, the director now owns 48,433,261 shares in the company, valued at $121,083,152.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lexicon Pharmaceuticals Stock Down 0.4 %

LXRX opened at $2.37 on Tuesday. Lexicon Pharmaceuticals, Inc. has a 12 month low of $1.31 and a 12 month high of $6.33. The company has a market cap of $354.54 million, a P/E ratio of -3.82 and a beta of 1.50. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.25. The business’s 50-day moving average price is $2.20 and its 200-day moving average price is $2.32.

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative return on equity of 75.21% and a negative net margin of 29,310.39%. During the same period in the previous year, the firm posted ($0.15) earnings per share. On average, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in LXRX. Russell Investments Group Ltd. lifted its position in shares of Lexicon Pharmaceuticals by 3.4% during the 4th quarter. Russell Investments Group Ltd. now owns 250,317 shares of the biopharmaceutical company’s stock valued at $985,000 after buying an additional 8,130 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Lexicon Pharmaceuticals by 56.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 772,978 shares of the biopharmaceutical company’s stock worth $3,046,000 after purchasing an additional 277,540 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in Lexicon Pharmaceuticals by 1.4% in the 4th quarter. Pinnacle Associates Ltd. now owns 2,127,662 shares of the biopharmaceutical company’s stock worth $8,383,000 after purchasing an additional 30,015 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Lexicon Pharmaceuticals by 33.3% in the 4th quarter. Victory Capital Management Inc. now owns 27,951 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 6,986 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $143,000. 90.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Citigroup boosted their price target on shares of Lexicon Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, July 1st.

About Lexicon Pharmaceuticals

(Get Rating)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.

See Also

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.